VCCRI: 'Heart in a Box'

An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.

VCCRI: 'Heart in a Box'

September 6, 2022
An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.
Read Transcript

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

An Australian method of preserving donated hearts has boosted the number of successful transplants and new data shows recipients of these “dead” tickers have similar survival rates to traditional transplants.

There have been 78 heart transplants conducted through Sydney’s St Vincent’s Hospital and the Victor Chang Cardiac Research Institute’s world-first DCD (donation after circulatory death) process, a technique that has since been adopted by several hospitals abroad.

While donated hearts once had to come from brain-dead people whose hearts were still beating, the DCD method, pioneered in Sydney, means donations can take place after the heart has stopped. Within half an hour of life support being switched off, the heart is extracted and flushed with an oxygenated blood preservation solution before being transported in a special machine to its recipient.

“These are hearts that would not otherwise have been used,” said Professor Peter MacDonald, a senior cardiologist at St Vincent’s Hospital and leader of the DCD heart transplant team.

When Sydneysider Ross Tripodi woke up from his DCD heart transplant in April 2020, he assumed it must not have happened: he didn’t feel like he had just had a big surgery, he felt better than before.

“I was bright-eyed and bushy-tailed,” the 57-year-old recalled. “I turned to the nurse and said, ‘Oh, you haven’t done the transplant?’”

Tripodi was diagnosed with cardiomyopathy – an enlarged heart – aged 49. In 2019, experiencing organ failure, he was warned he would not survive another year without a transplant.

“I got home to see my daughter turn 21, most people take that for granted, but, for me, it was a lot,” he said. “There’s never a bad day anymore. You don’t sweat the little things. I’m just grateful for anything.”

A review of the first eight years of the program, published in the journal Transplantation, showed the new technology had increased the number of transplants performed at the hospital by 25 per cent.

It also demonstrated, in its small sample of 74 transplants, a negligible difference in one-year and five-year survival rates between people who received a heart via either method.

The review’s lead author Dr Yashutosh Joshi said it demonstrated there was “no reason why we shouldn’t” pursue DCD when appropriate for the patient. The five-year survival rate for a DCD heart transplant was 88 per cent, compared with 81 per cent for a brain-dead transplant.

“We don’t want to overstate the benefits of DCD over brain death because it’s still a small sample,” MacDonald said, noting heart transplant was generally a very successful procedure.

The newer method also comes with a time pressure that does not exist in traditional heart transplants. Joshi – who has travelled to collect donated hearts from as far as Darwin – described the program as “essentially 24/7”, with minutes saved by harvesting the organ in an anaesthetic bay, as opposed to in intensive care, contributing to success.

But, said Dr Emily Granger, a surgeon at St Vincent’s, the hearts donated through the DCD system are generally of better quality.

“When someone is brain-dead they have often had a surge of adrenaline which impacts the heart, but in these people their heart is in much better condition,” said Granger, who is also the president-elect of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.

At St Vincent’s, the only Australian hospital using the method, DCD procedures now account for 30 per cent of heart transplants. In the UK, where DCD transplants started in 2015, they account for almost half of procedures.

Hospitals in the US, Spain, Belgium and the Netherlands have also adopted the technology.

MacDonald said he expected the cost of the “heart in a box” – about $50,000 per use – would mean that it would probably never make up the majority of transplants, but it was an important way to increase organ donation.

The Organ and Tissue Authority’s national medical director, Associate Professor Helen Opdam, agreed, noting the pandemic had impacted the number of available donors and people receiving transplants.

“Heart transplantation from donation after circulatory death enables more people to have their wishes to donate honoured, as it has expanded the situations in which donation is possible,” she said. “It also means more people will have the chance to receive a life-saving heart transplant.”

St Vincent’s and the Victor Chang Cardiac Research Institute are now working with researchers at the University of Queensland to improve the viability of donated hearts, through a novel project involving the use of protein from funnel web spider venom in the preservation process.

 This article was originally posted by The Sydney Morning Herald here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Sydney Morning Herald, published on September 6, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
July 1, 2026

Improving care for adults with motor neuron diseases

Building better care for adults living with Motor Neuron Disease and Spinal Muscular Atrophy.

Read More
July 1, 2026

Understanding fatigue in young people with Charcot-Marie-Tooth disease

Developing a tool to improve understanding, research and care.

Read More
Picture: Professor Gina Ravenscroft and her teamPicture: Professor Gina Ravenscroft and her teamPicture: Professor Gina Ravenscroft and her teamPicture: Professor Gina Ravenscroft and her team
July 1, 2026

Giving families living with rare diseases the answers they need

Supporting research to improve the diagnosis of rare genetic neuromuscular diseases and build the foundations for future treatments.

Read More
Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher
July 1, 2026

Understanding spinal cord injury recovery

The world's first molecular map of spinal cord injury across time and injury levels

Read More
Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium
July 1, 2026

Building the foundations for faster progress against brain cancer

Uniting researchers, clinicians and patients to accelerate research and improve patient care.

Read More
July 1, 2026

Accelerating CAR-T cell therapies for patients in need 

Bringing innovative cancer therapies closer to patients.

Read More
July 1, 2026

Supporting babies at high risk of cerebral palsy from the very beginning

Testing a family-centred early intervention program to improve outcomes for infants and support parents during the first critical months of life.

Read More
July 1, 2026

Making early cerebral palsy screening more accessible

Exploring new ways to identify babies at risk of cerebral palsy sooner and support better outcomes.

Read More
December 5, 2023

Prof Daniel MacArthur | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Daniel MacArthur, the Director of the Centre for Population Genomics.

Read More
December 5, 2023

Prof Michelle Simmons AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Michelle Simmons, the CEO and Founder of Silicon Quantum Computing.

Read More
December 5, 2023

Prof Misty Jenkins AO | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Misty Jenkins. Misty is a NHMRC fellow and laboratory head of the Immunology Division at the Walter and Eliza Hall Institute.

Read More
Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.
November 15, 2023

Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Read More
November 10, 2023

Big thinkers in hunt for brain cancer cure

“Brain cancer is rare, but for people who do get it the prognosis is not good,” Assistant Professor Jenkins tells The Australian.

Read More
April 20, 2023

Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Read More
February 14, 2023

Bringing Equity and Diversity to Genomic Medicine

Professor Daniel MacArthur, Director of the Centre for Population Genomics has big goals to bring equity and diversity into genomic medicine in Australia, something surprisingly inadequate presently.

Read More